Olmesartan medoxomil

Research use only, not for human use.

An angiotensin II receptor antagonist which has been used for the treatment of high blood pressure.

An angiotensin II receptor antagonist which has been used for the treatment of high blood pressure. Hypertension Approved(In Vitro):Inhibition of Arachidonic acid (AA) metabolism by angiotensin II receptor blockers (ARBs) is detected in a concentration-dependent manner with IC50 of Olmesartan (66.2 μM). Olmesartan medoxomil (OLM) is a potent and selective angiotensin AT1 receptor blocker.(In Vivo):The efficacy of Olmesartan (20 mg/kg) studied in db/db diabetic mice for a period of 12 weeks starting from week 10 to 12 of age. The db/db mice have 11.7 fold increased albuminuria in comparison to control mice at week 22 to 24 of age. Twelve weeks Olmesartan administration significantly reduces albuminuria in db/db mice by 77% as compared with placebo treated db/db mice. The albumin/creatinine ratio (ACR) is increased in db/db mice in comparison to control mice by 7.1 fold and Olmesartan treatment significantly decreases ACR by 59% in db/db mice.

——

——

CS-866

GPCR/G Protein

Angiotensin Receptor

angiotensinIIreceptor

Cardiovascular Disease

Hypertension

144689-63-4

558.5851

C29H30N6O6

>98% (HPLC)

10 mM in DMSO

O=C(C1=C(C(C)(O)C)N=C(CCC)N1CC2=CC=C(C3=CC=CC=C3C4=NN=NN4)C=C2)OCC5=C(C)OC(O5)=O

1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester

(-20℃)

With Ice Pack

≥ 2 years